After 14 years of research, the condition long known as PCOS has been officially renamed — a change researchers say will reshape diagnosis, care and awareness for the roughly 170 million women affected worldwide. Polycystic Ovary Syndrome, the name millions of patients have learned to live with, is now Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The shift reflects what doctors say the condition actually is: a complex, multisystem hormonal and metabolic disorder, not a disease defined by ovarian cysts.
The rename was led by professor Helena Teede, director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health.
Why Was PCOS Renamed to PMOS?
The core problem with the PCOS label, researchers argued, is that it was medically misleading. The condition does not actually involve an increase in pathological ovarian cysts, and the name fails to capture the broader endocrine, metabolic, dermatological and psychological symptoms patients live with. According to the study, up to 70 percent of affected individuals remain undiagnosed, in part because the name narrows clinical focus to the ovaries.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Teede said, per Endocrine Society. “It was heartbreaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition. While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition.”
What Is PMOS?
Polyendocrine Metabolic Ovarian Syndrome is a hormonal imbalance in which the ovaries produce excess androgens, throwing off reproductive hormones. According to Cleveland Clinic, patients often experience irregular menstrual cycles, missed periods and unpredictable ovulation. Small follicle cysts may appear on ultrasound due to a lack of ovulation, but cysts are not required for a diagnosis.
The condition reaches well beyond the reproductive system. Researchers describe it as a multisystem disorder driven by insulin, androgens, neuroendocrine hormones and ovarian hormones working in concert — which is why the new name highlights the endocrine and metabolic dimensions rather than the ovaries alone.
How PMOS Is Diagnosed
Diagnosis of Polycystic Ovary Syndrome — now PMOS — happens only after other possible disorders are ruled out, and the criteria differ by age. The study outlines the current standards clinicians use worldwide.
In adults 20 and older, diagnosis requires at least two of three criteria:
- Irregular or absent ovulation (oligo-anovulation)
- Elevated androgen levels or symptoms of excess androgens (hyperandrogenism)
- Polycystic ovaries on ultrasound or elevated anti-Müllerian hormone (AMH) levels
PMOS Has Symptoms That Go Far Beyond the Ovaries
One of the central arguments for the rename is that the old label hid how much of the body PMOS affects. The study describes the condition’s significant long-term health and economic impacts, and the symptom list spans nearly every major system.
Reported symptoms include:
- Metabolic: obesity, insulin resistance, type 2 diabetes, high blood pressure, abnormal cholesterol, fatty liver disease, cardiovascular disease and sleep apnea
- Reproductive: irregular menstrual cycles, infertility, pregnancy complications and increased endometrial cancer risk
- Psychological: depression, anxiety, eating disorders and reduced quality of life
- Dermatological: acne, hair thinning and excess facial or body hair
The study notes the broad clinical picture has long been poorly captured by the term PCOS, contributing to widespread knowledge gaps and patient dissatisfaction.
How the Global Consensus Surrounding PMOS Was Built
The name change was not a unilateral decision. To evaluate whether renaming was justified, researchers organized a multistep global consultation involving 56 medical, scientific and patient advocacy organizations. They collected feedback from more than 14,000 patients and health professionals worldwide through iterative surveys, workshops, modified Delphi consensus methods and implementation analyses. The study was published in The Lancet.
For the roughly 170 million women of reproductive age living with the condition, the rename is more than semantic. Teede and her colleagues argue it will accelerate diagnosis, expand research funding and reshape how doctors talk with patients about what is happening in their bodies.
